Previous 10 | Next 10 |
2024-04-09 12:18:00 ET More on InMode InMode's Quest For Growth Amidst Aesthetic Adversities InMode Does Not Look Pretty Right Now: Time To Buy InMode: The Inefficacy Of A Company's Investment Strategy Survey finds GLP-1 users more inclined to get aesthetic p...
A look at the top 10 most actives in the United States Selina Hospitality PLC (SLNA) rose 28.8% to $0.0515 on volume of 62,068,605 shares Laser Photonics Corporation (LASE) rose 172.7% to $3.9 on volume of 54,588,758 shares WiSA Technologies Inc. (WISA) fell 6.1% to $0.0217 on volume of 2...
2024-04-09 08:26:39 ET More on Pre-market losers & stocks. HUB Cyber Security jumps 39% on QPoint Technologies acquisition Acorda Therapeutics announces Nasdaq delisting notification Financial information for Acorda Therapeutics Financial information for ...
2024-04-02 21:34:12 ET Summary InMode's Q4 revenue dropped YOY; management optimistic about new platforms despite industry challenges. High dependence on U.S. revenue from minimally invasive procedures; facing increasing competition in RF technology. R&D spending at 3% of ...
2024-04-02 14:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-26 04:21:43 ET Summary Despite a highly profitable business model and a strong position in the medical aesthetics industry, INMD stock is down -33% over the last 12 months. Macroeconomic pressures, political risks in InMode’s home country Israel, and, to a lesser ex...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In InMode To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - March 18, 2024) - Faruqi & Faruqi, LLP, a leading national s...
2024-03-17 17:09:16 ET More on AbbVie, Evolus, etc. AbbVie Inc. (ABBV) Barclays 26th Annual Global Healthcare Conference (Transcript) AbbVie: Comeback Expected After Humira Patent Expiration AbbVie Stock: I Was So Wrong, But This Is Way Too Fast Evolus prices...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In InMode To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - March 10, 2024) - Faruqi & Faruqi, LLP, a leading national s...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In InMode To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - March 6, 2024) - Faruqi & Faruqi, LLP, a leading national se...
News, Short Squeeze, Breakout and More Instantly...
DOMA Perpetual Sends Letter to the Board of Directors of InMode Urging the Execution of a 40% Tender Offer PR Newswire Believes InMode's Cash Balance of Roughly 55% of its Market Cap is Grossly Inefficient Asserts the Current Valuation Offers an Unprecedented Oppo...
2024-07-23 06:00:08 ET Matthew Taylor from Jefferies issued a price target of $19.00 for INMD on 2024-07-23 05:00:00. The adjusted price target was set to $19.00. At the time of the announcement, INMD was trading at $17.75. The overall price target consensus is at $34.50...
Morpheus8 Secures First and Only FDA Clearance for Soft Tissue Contraction for Fractional Radiofrequency Microneedling PR Newswire IRVINE, Calif. , July 17, 2024 /PRNewswire/ -- InMode Ltd. (NASDAQ: INMD), a leading global provider of innovative medical technolog...